| 翻訳と辞書 |
| Advanced Accelerator Applications ： ウィキペディア英語版 |
Advanced Accelerator Applications
Advanced Accelerator Applications (AAA) is a pharmaceutical group specialised in the field of Molecular Nuclear Medicine.〔(PrivateEquityWire, "Advanced Accelerator Applications completes fundraising", Feb 18th, 2014 )〕
The group operates in all three segments of Molecular Nuclear Medicine (PET, SPECT and Therapy) to diagnose and treat serious conditions in the fields of oncology (cancer), neurology, cardiology, infectious and inflammatory diseases.〔(Il Sole 24 Ore, “Dal Cern and Biopark canavese”, March 12th, 2014 )〕
Molecular Nuclear Medicine is a medical specialty using small amounts of radioactive materials, called radiopharmaceuticals, to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras (PET and SPECT) that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can be used to treat certain types of cancer and other diseases.〔(SNMMI, "About Nuclear Medicine & Molecular Imaging" )〕
Molecular Imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes. Nuclear medicine procedures can often identify abnormalities very early in the progress of a disease — long before many medical problems are apparent with other diagnostic tests.〔(SNMMI, "Glossary of Molecular Imaging Terms" )〕
==History==
AAA was created in 2002 by Italian physicist Stefano Buono to exploit a patent from the European Organization for Nuclear Research (CERN).〔(AdnKronos,“ Research: from Rubbia to AAA, great success for an Italian physicist with European company”, March 19th, 2010 )〕 Today AAA trades on the Nasdaq Global Select Market under the ticker “AAAP.” The first day of trading was 11 November 2015. 〔(Insider Monkey Stocks Hot on the Market on Wednesday 11 November." )〕
The group currently has 17 production and research & development facilities that manufacture both diagnostic and therapeutic Molecular Nuclear Medicine products, and over 390 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S. and Canada).
AAA’s founder and CEO is Stefano Buono. AAA's Board of Directors includes Dr Yvonne Greenstreet, Steven Gannon, Christian Merle, Leopoldo Zambeletti, Stefano Buono, Kapil Dhingra,〔(Molecular Imaging, "Advanced Accelerator Applications keen on board consult from Kapil Dhingra", May 7th, 2014 )〕 Muriel de Szilbereky and Claudio Costamagna.〔(Market Watch, "Kapil Dhingra, Former Head of Roche Oncology, Joins AAA Board of Directors", April 29th, 2014 )〕
Claudio Costamagna serves as Chairman since June 2012.〔(MF Dow Jones, “Claudio Costamagna new Chairman of AAA”, June 21st, 2012 )〕
AAA announced its full-year results for 2014, with sales of €69.9 million (+29.8% vs. 2013).〔(Yahoo Finance,"AAA Reports 29.8% Sales Growth in 2014 While Continuing to Show Significant Clinical Progress Across Both Therapeutic and Diagnostic Platforms", April 9th, 2015 )〕〔(Aunt Minnie, "AAA reports sales boost in 2014", April 10th, 2015 )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Advanced Accelerator Applications」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|